Study guide

9.4 Common Dermatologic Conditions, Cutaneous Manifestations of Systemic Disease, & Skin Cancers

Medical Council of Canada Qualifying Examination Part I MCCQE Part I

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview, Blueprint & Canadian Medical Practice

1.1 MCCQE Part I Format, Scoring (439 Scale), & Strategy 1.2 The MCC Blueprint Matrix: Dimensions of Care & Physician Activities 1.3 Canadian Healthcare System, CanMEDS Roles, & Interprofessional Care 1.4 Evidence-Based Medicine, Study Design, & Clinical Statistics

2 Chapter 2: Population Health, Health Promotion & Preventive Care

2.1 Canadian Task Force on Preventive Health Care (CTFPHC) Screening Guidelines 2.2 Immunization Schedules (NACI) & Vaccine-Preventable Diseases across Lifespan 2.3 Disease Prevention, Lifestyle Counselling, & Harm Reduction 2.4 Outbreak Management, Disease Surveillance, & Infection Control 2.5 Occupational, Environmental, & Travel Medicine in Canada

3 Chapter 3: Internal Medicine — Cardiovascular & Respiratory Systems

3.1 Hypertension Canada 2020/2025 Guidelines, Dyslipidemia, & Primary Prevention 3.2 Ischemic Heart Disease, Acute Coronary Syndromes, & Heart Failure Management 3.3 Arrhythmias, Valvular Heart Disease, & Infective Endocarditis 3.4 Asthma, COPD, & Respiratory Failure (CTS Guidelines) 3.5 Thromboembolic Disease (DVT/PE), Pneumonia, & Pleural Effusions

4 Chapter 4: Internal Medicine — GI, Endocrine, Renal & Hematology/Oncology

4.1 Gastrointestinal Disorders, Acute Abdomen, & Liver/Biliary Disease 4.2 Diabetes Canada 2020/2025 Guidelines & Glycemic Management 4.3 Thyroid, Adrenal, Pituitary, & Electrolyte Disturbances 4.4 Acute Kidney Injury (AKI), Chronic Kidney Disease (CKD), & Nephrology 4.5 Hematology, Anemia Evaluation, Transfusion Medicine, & Common Cancers

5 Chapter 5: General Surgery, Orthopedics, & Emergency Care

5.1 Surgical Evaluation, Preoperative Clearance, & Postoperative Complications 5.2 Trauma Management (ATLS Protocol) & Burns 5.3 Acute Surgical Conditions (Appendicitis, Cholecystitis, Bowel Obstruction) 5.4 Fractures, Dislocations, Joint Pain, & Musculoskeletal Emergencies 5.5 Vascular Emergencies, Wound Care, & Shock Recognition

6 Chapter 6: Pediatrics & Adolescent Health

6.1 Pediatric Growth, Developmental Milestones, & Well-Child Examinations 6.2 Neonatal Resuscitation, Jaundice, & Common Congenital Anomalies 6.3 Pediatric Respiratory Emergencies (Croup, Bronchiolitis, Asthma) 6.4 Common Pediatric Infections, Exanthems, & Fever of Unknown Origin 6.5 Pediatric Abdominal Pain, Dehydration, & Fluid Management

7 Chapter 7: Obstetrics & Gynecology

7.1 Routine Antepartum Care, Screening, & Prenatal Diagnosis (SOGC Guidelines) 7.2 Medical Complications of Pregnancy (Preeclampsia, Gestational Diabetes, Infections) 7.3 Labor, Intrapartum Management, & Postpartum Complications/Hemorrhage 7.4 Abnormal Uterine Bleeding, Gynecologic Infections, & Contraception/Menopause 7.5 Gynecologic Oncology & Pelvic Mass Evaluation

8 Chapter 8: Psychiatry & Mental Health

8.1 Mood Disorders (Depression, Bipolar) & Suicide Risk Assessment 8.2 Anxiety Disorders, OCD, PTSD, & Somatic Symptom Disorders 8.3 Psychotic Disorders & Schizophrenia Management 8.4 Substance Use Disorders, Withdrawal Syndromes, & Harm Reduction 8.5 Pediatric, Perinatal, & Geriatric Psychiatry (Cognitive Impairment / Delirium)

9 Chapter 9: Neurology, Rheumatology, & Dermatology

9.1 Acute Stroke, TIA, & Neurovascular Emergencies 9.2 Headaches, Seizures, Movement Disorders, & Neuromuscular Disease 9.3 Inflammatory Arthritides (RA, Gout, SpA) & Systemic Autoimmune Diseases (SLE, Vasculitis) 9.4 Common Dermatologic Conditions, Cutaneous Manifestations of Systemic Disease, & Skin Cancers 9.5 Musculoskeletal Soft Tissue Injuries, Back Pain, & Physical Medicine

10 Chapter 10: Legal, Ethical, & Professional Behaviours in Canadian Practice

10.1 Informed Consent, Capacity Assessment, & Substitute Decision-Making (CMPA) 10.2 Medical Confidentiality, Privacy Laws (PIPEDA/PHIPA), & Disclosure of Harm 10.3 CMA Code of Ethics, Professionalism, & Physician Health/Boundary Issues 10.4 Mandatory Reporting (Child/Elder Abuse, Driving Safety, Fitness to Practice) & Quality/Safety

9.4 Common Dermatologic Conditions, Cutaneous Manifestations of Systemic Disease, & Skin Cancers

Key Takeaways Explain This Topic AI

Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) represent life-threatening dermatologic emergencies requiring immediate withdrawal of offending medications and burn unit care.

Pemphigus vulgaris features flaccid bullae, mucosal involvement, and positive Nikolsky sign due to intraepidermal acantholysis, whereas bullous pemphigoid features tense bullae and negative Nikolsky sign.

Erythema nodosum presents as painful, erythematous nodules on the shins, triggered by sarcoidosis, IBD, streptococcal infection, or medications.

Pyoderma gangrenosum presents with rapidly expanding painful ulcers with violaceous, undermined borders exhibiting pathergy; surgical debridement is strictly contraindicated.

Melanoma prognosis is primarily determined by Breslow depth of invasion; suspicious pigmented lesions displaying ABCDE criteria require full-thickness excisional biopsy.

Last updated: July 2026

Severe Cutaneous Adverse Reactions (SCARs) & Dermatologic Emergencies

Severe Cutaneous Adverse Reactions represent life-threatening, immune-mediated drug reactions requiring rapid clinical recognition, immediate drug cessation, and intensive supportive management.

Stevens-Johnson Syndrome (SJS) & Toxic Epidermal Necrolysis (TEN)

SJS and TEN exist on a severity spectrum defined by the percentage of Body Surface Area (BSA) exhibiting epidermal detachment:

SJS: < 10 % <10\% < 10% BSA detachment.

SJS / TEN Overlap: 10 % – 30 % 10\%\text{--}30\% 10% – 30% BSA detachment.

  • TEN: > 30 % >30\% > 30% BSA detachment. [Prodromal Phase (1-3 Days)]
  • └─ Fever, malaise, arthralgias, upper respiratory symptoms
  • [Mucocutaneous Eruption Phase]
  • ├─ Painful, dusky red macules & targetoid lesions spreading rapidly
  • ├─ Flaccid blisters forming sheet-like epidermal sloughing
  • ├─ Positive Nikolsky Sign (epidermal detachment induced by gentle lateral pressure)
  • └─ Severe Mucosal Involvement (>= 2 sites: oral erosions, conjunctivitis, genital ulceration)
  • [Emergency Interventions]
  • ├─ 1. IMMEDIATELY DISCONTINUE ALL SUSPECTED MEDICATIONS
  • ├─ 2. Transfer to Burn Unit or Intensive Care Unit
  • ├─ 3. Aggressive Fluid Resuscitation & Wound Management
  • └─ 4. Urgent Ophthalmology Consult (prevent ocular scarring & blindness)
  • Common Drug Triggers

Allopurinol (most common cause in North America).

Antiepileptics: Lamotrigine, Carbamazepine, Phenytoin, Phenobarbital.

Antibiotics: Sulfonamides (Trimethoprim-Sulfamethoxazole), Penicillins, Cephalosporins.

NSAIDs: Meloxicam, Piroxicam.

  • Autoimmune & Inflammatory Dermatoses
  • Autoimmune Bullous Diseases

Differentiation between Pemphigus Vulgaris and Bullous Pemphigoid is a classic high-yield topic for medical examinations.

  • Feature Pemphigus Vulgaris Bullous Pemphigoid
  • Target Antigen Desmoglein-3 and Desmoglein-1 (Desmosomes) BP180 and BP230 (Hemidesmosomes)
  • Level of Cleavage Intraepidermal (Acantholysis) Subepidermal

Blister Appearance Flaccid , thin-walled, ruptures easily leaving painful erosions Tense , firm, intact bullae on normal or erythematous skin

  • Mucosal Involvement Extensive & Common (oral painful ulcers precede skin lesions) Rare or mild
  • Nikolsky Sign Positive Negative
  • Typical Age 40 to 60 years > 60 >60 > 60 years (elderly)

Direct Immunofluorescence Intercellular "chicken-wire" IgG pattern Linear IgG and C3 deposition along Basement Membrane Zone

First-Line Treatment High-dose oral Prednisone + Rituximab High-potency topical steroids (Clobetasol) or systemic steroids

Papulosquamous & Atopic Conditions

Psoriasis: Chronic inflammatory skin disease presenting with well-demarcated erythematous plaques covered by silvery-white scales on extensor surfaces (elbows, knees, scalp). Features include Auspitz sign (pinpoint bleeding when scale is scraped) and Koebner phenomenon (development of psoriatic lesions at sites of mechanical trauma). Treated with topical corticosteroids + calcipotriol (Vitamin D analog), phototherapy, or systemic TNF/IL-17/IL-23 inhibitors.

Atopic Dermatitis (Eczema): Pruritic, ill-demarcated erythematous papules and plaques on flexural surfaces (antecubital and popliteal fossae). Associated with personal/family history of atopy (asthma, allergic rhinitis). Managed with frequent emollients, topical corticosteroids, or topical calcineurin inhibitors (Tacrolimus).

Cutaneous Manifestations of Systemic Disease

Skin lesions frequently provide the first diagnostic clue to underlying systemic pathology.

Erythema Nodosum

Clinical Presentation: Painful, tender, warm, erythematous nodules typically located symmetrically on the anterior shins. Histology reveals septal panniculitis without vasculitis.

Etiologic Causes:

Sarcoidosis: Part of Löfgren syndrome (triad of Erythema Nodosum, bilateral hilar lymphadenopathy, and migratory polyarthralgia).

Infections: Streptococcal pharyngitis, Tuberculosis, Coccidioides .

Inflammatory Bowel Disease: Crohn's disease or Ulcerative Colitis flare.

Medications: Oral Contraceptive Pills, Sulfonamides.

Pyoderma Gangrenosum

Clinical Presentation: Inflammatory, non-infectious ulcerative skin condition initiating as a painful pustule that rapidly expands into an ulcer with violaceous, undermined borders and a purulent base.

Systemic Associations: Inflammatory Bowel Disease (IBD), Rheumatoid Arthritis, Myeloproliferative disorders.

Pathergy & Management Rule: Pyoderma gangrenosum exhibits pathergy (exacerbation of ulceration following minor trauma or surgical intervention).

Exam Trap: Surgical debridement is strictly contraindicated as it causes dramatic enlargement of the ulcer. First-line therapy consists of systemic corticosteroids or cyclosporine.

Acanthosis Nigricans & Dermatomyositis

Acanthosis Nigricans: Hyperpigmented, velvety hyperkeratotic plaques in flexural folds (axillae, neck). Benign form associated with Insulin Resistance, Obesity, T2DM, and PCOS. Rapid-onset, widespread malignant form associated with Gastrointestinal Adenocarcinoma (gastric cancer).

Dermatomyositis: Autoimmune myopathy with characteristic cutaneous markers: Heliotrope rash (violaceous eruption over upper eyelids with periorbital edema), Gottron papules (erythematous/violaceous papules over MCP and IP joints), Shawl sign, and V-sign. Requires age-appropriate malignancy screening (ovarian, lung, GI, breast cancer).

  • Cutaneous Oncology
  • Basal Cell Carcinoma (BCC)

Most common skin malignancy ( 80 % ~80\% 80% of non-melanoma skin cancers).

Presentation: Pearly, translucent papule or nodule with telangiectasias, central ulceration, and rolled borders on sun-exposed head or neck.

Behavior & Management: Locally invasive but extremely low metastatic potential. Treated with standard excision or Mohs micrographic surgery (for high-risk facial sites).

Squamous Cell Carcinoma (SCC)

Second most common skin cancer, arising from epidermal keratinocytes. Precursor lesion is Actinic Keratosis (rough, scaly, sand-paper-like erythematous papule).

Presentation: Firm, hyperkeratotic, erythematous nodule or plaque with scaling, crusting, or central ulceration.

Metastatic Potential: Higher risk of metastasis than BCC, especially when located on the lip, ear, immunosuppressed individuals, or arising within chronic scars ( Marjolin ulcer ). Treated with surgical excision.

Melanoma

Melanoma is the most lethal cutaneous malignancy, arising from melanocytic transformation.

ABCDE Diagnostic Criteria

A symmetry: One half of lesion does not match the other.

B order Irregularity: Scalloped, notched, or blurred borders.

C olor Variation: Mixed shades of brown, black, red, white, or blue.

D iameter: > 6 mm >6\text{ mm} > 6 mm (size of a pencil eraser).

E volving: Changes in size, shape, color, or new onset of bleeding or itching.

Biopsy Rule & Staging

Exam Trap: In suspected melanoma, NEVER perform a partial shave biopsy or punch biopsy through the center of the lesion. Always perform a full-thickness excisional biopsy with 1 – 3 mm 1\text{--}3\text{ mm} 1 – 3 mm margins down to subcutaneous fat to preserve micro-architecture for pathological assessment.

Prognostic Factor: Breslow depth of invasion (measured in millimeters from the epidermal granular layer to the deepest tumor cell) is the single most important determinant of survival and staging.

Surgical Margins: Wide local excision margins are dictated by Breslow depth ( 1 cm 1\text{ cm} 1 cm margin for depth < 1 mm <1\text{ mm} < 1 mm ; 2 cm 2\text{ cm} 2 cm margin for depth > 2 mm >2\text{ mm} > 2 mm ). Sentinel Lymph Node Biopsy (SLNB) is indicated for lesions with Breslow depth > 0.8 – 1.0 mm >0.8\text{--}1.0\text{ mm} > 0.8 – 1.0 mm or ulcerated lesions.

Loading diagram... Autoimmune Bullous Dermatoses & Cutaneous Emergencies Differential Flowchart